Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, double-blind, randomized, multisite trial of the efficacy, safety, and tolerability of the fixed combination torcetrapib/atorvastatin administered orally, once daily for 12 months, compared to atorvastatin alone, titrated based on NCEP [National Cholesterol Education Program] ATP [Adult Treatment Panel]-III LDL-C [low density lipoprotein cholesterol] goals in subjects with Fredrickson types IIa and IIb dyslipidemias

Next Previous
Trial Profile

A phase 3, double-blind, randomized, multisite trial of the efficacy, safety, and tolerability of the fixed combination torcetrapib/atorvastatin administered orally, once daily for 12 months, compared to atorvastatin alone, titrated based on NCEP [National Cholesterol Education Program] ATP [Adult Treatment Panel]-III LDL-C [low density lipoprotein cholesterol] goals in subjects with Fredrickson types IIa and IIb dyslipidemias

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2006

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
  • Indications Lipid metabolism disorders
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 05 Dec 2006 Status change
  • 25 Sep 2006 Status change
  • 29 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top